The company is iniitally focused on acute and chronic treatments for pulmonary aspergillosis and its lead product, opelconazole, is being developed initially for the treatment of invasive pulmonary aspergillosis.

In December 2022, the UK-based company announced it had raised $52 million in a Series C extension round led by new investors Pictet Alternative Advisors and Vivo Capital.

Pulmocide aims to use the proceeds to further fund clinical development, manufacturing scale-up, and preparation for potential commercialization of opelconazole.